Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 210,760,736
  • Shares Outstanding, K 3,101,247
  • Annual Sales, $ 54,073 M
  • Annual Income, $ 7,035 M
  • EBIT $ 10,562 M
  • EBITDA $ 17,250 M
  • 60-Month Beta 0.40
  • Price/Sales 3.80
  • Price/Cash Flow 10.52
  • Price/Book 4.99

Options Overview Details

View History
  • Implied Volatility 26.16% ( -2.65%)
  • Historical Volatility 37.97%
  • IV Percentile 68%
  • IV Rank 32.94%
  • IV High 47.30% on 04/08/25
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 0.51
  • Today's Volume 5,499
  • Volume Avg (30-Day) 9,109
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 190,842
  • Open Int (30-Day) 161,903

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 1.12
  • Number of Estimates 4
  • High Estimate 1.16
  • Low Estimate 1.07
  • Prior Year 0.99
  • Growth Rate Est. (year over year) +13.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
66.16 +4.01%
on 05/14/25
72.69 -5.34%
on 05/06/25
+1.76 (+2.62%)
since 04/16/25
3-Month
61.24 +12.36%
on 04/09/25
78.36 -12.18%
on 03/05/25
-4.77 (-6.48%)
since 02/14/25
52-Week
61.24 +12.36%
on 04/09/25
87.68 -21.52%
on 08/30/24
-8.23 (-10.68%)
since 05/16/24

Most Recent Stories

More News
Stocks Finish Higher on Fed Rate Cut Hopes

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.08%. June E-mini S&P...

GOOGL : 166.19 (+1.36%)
DE : 531.48 (+2.94%)
APP : 362.34 (-1.16%)
CSCO : 63.62 (-1.00%)
FI : 166.66 (+4.73%)
STE : 251.59 (+1.91%)
FL : 23.85 (-0.21%)
$IUXX : 21,427.94 (+0.43%)
AMGN : 272.41 (+0.27%)
PFE : 22.83 (+1.02%)
UNH : 291.91 (+6.40%)
ASML : 748.10 (-1.35%)
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales

Bayer AG BAYRY reported first-quarter 2025 core earnings of 66 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimates of 63 cents. The company reported earnings of 77 cents...

BAYRY : 6.3700 (-0.78%)
AZN : 68.81 (+1.25%)
JNJ : 151.33 (+1.15%)
REGN : 594.32 (+1.59%)
Stocks Finish Moderately Higher on US-UK Trade Deal and Hope for Weekend China Talks

The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +0.58%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.62%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.98%. June E-mini S&P...

MSTR : 399.80 (+0.70%)
MPC : 164.12 (-0.71%)
APP : 362.34 (-1.16%)
TAP : 56.85 (+1.03%)
ADI : 227.11 (unch)
SLB : 35.77 (+0.14%)
AMGN : 272.41 (+0.27%)
COIN : 266.46 (+9.01%)
OXY : 43.04 (-0.76%)
FANG : 141.13 (-0.58%)
AMD : 117.17 (+1.90%)
SPY : 594.20 (+0.63%)
Tempus AI Stock: Time to Double Down or Cut and Run?

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.

AZN : 68.81 (+1.25%)
TEM : 65.49 (+4.62%)
Vanguard FTSE Developed Markets ETF: A Good Hedge Against the U.S. Market?

If you’re worried about U.S. stocks right now, you may want to consider deploying more of your ...

VEA : 54.50 (+0.22%)
SAP : 296.41 (+0.70%)
AZN : 68.81 (+1.25%)
NVS : 109.59 (+1.04%)
SHEL : 66.62 (-0.08%)
Amgen's Q1 Earnings Beat Estimates, Key Drugs Drive Sales Growth

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 per share. Earnings rose 24% year over year as higher revenues were partially...

AZN : 68.81 (+1.25%)
JNJ : 151.33 (+1.15%)
AMGN : 272.41 (+0.27%)
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this. After all, shares...

AZN : 68.81 (+1.25%)
TEM : 65.49 (+4.62%)
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty

/CNW/ -- Equity Insider News Commentary – Optimism in the field of oncology is on the rise, thanks to the National Institutes of Health's latest annual report,...

ONCY : 0.4676 (-6.54%)
BCT.TO : 4.08 (+0.74%)
BCTXW : 0.0692 (+16.30%)
AZN : 68.81 (+1.25%)
STRO : 0.9116 (+3.77%)
BCTX : 2.94 (+0.68%)
ONC.TO : 0.65 (-5.80%)
TEM : 65.49 (+4.62%)
Regulatory Breakthroughs and New Technologies Drive Healthcare’s AI Evolution

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – Within the modern western healthcare sector, artificial intelligence (AI) is being enlisted to streamline...

MSFT : 454.27 (+0.25%)
SOPH : 2.96 (-4.82%)
AVAI : 0.5725 (+7.80%)
AZN : 68.81 (+1.25%)
DOCS : 52.56 (-10.08%)
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs

AstraZeneca’s AZN first-quarter 2025 core earnings of $1.24 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.10. Core earnings of $2.49 per share rose 21% year over year on...

AZN : 68.81 (+1.25%)
MRK : 76.06 (+1.68%)
AMGN : 272.41 (+0.27%)
SNY : 51.68 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 69.87
2nd Resistance Point 69.36
1st Resistance Point 69.09
Last Price 68.81
1st Support Level 68.31
2nd Support Level 67.80
3rd Support Level 67.53

See More

52-Week High 87.68
Fibonacci 61.8% 77.58
Fibonacci 50% 74.46
Fibonacci 38.2% 71.34
Last Price 68.81
52-Week Low 61.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »